Astrazeneca Ab

Bayer Schering Pharma Ag

Bayer Pharma Aktiengesellschaft

Krister Henriksson

Magnus Munck Af Rosenschöld

Martin Hemmerling

Hartmut Rehwinkel

Markus Berger

Anders Eriksson

Balint Gabos

Stinabritt Nilsson

Svetlana Ivanova

Camilla Taflin

Matti Juhani Lepistö

Darren Mckerrecher

Karl Henrik Edman

Tomas Eriksson

Thomas Hansson

Jan Dahmén

Matti Juhani Lepisto

Peter Hansen

Darren McKerrecher

Lars Pettersson

Tomas Klingstedt

Jan Dahmen

Lena Kristina Bergstrom

Michael Bodkin

Matti Lepistö

Lena Bergström

Karl Edman

Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.

Chemical compounds 572

Compounds of formula (I): or a pharmaceutically acceptable salt thereof, compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).

Indazolyl sulphonamide derivatives useful as glucocorticoid modulators

The invention provides compounds of formula in which L, X, Y, Z, Z, R, R, Rand Ghave the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.

2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12

The invention provides compounds of formula (I) in which L, X, Y, Z, Z, R, R, Rand Ghave the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds of the invention are inhibitors of metalloproteinase MMP12 and are among other things useful for the treatment of obstructive airways diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12

The invention provides compounds of general formula (I) wherein m, n, Z, Z, R, R, R, R, R, R, Rand Rare as defined in the specification, process for their preparation, pharmaceutical compositions containing them and their use in therapy.

Compounds

The invention provides compounds of general formula (I) wherein Q, R, R, R, R, R, R, R, and Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Hydroxyalkyl compounds

Growing community of inventors

Lund, Sweden

Krister Henriksson